Entrada Therapeutics
TRDA
TRDA
47 hedge funds and large institutions have $334M invested in Entrada Therapeutics in 2022 Q4 according to their latest regulatory filings, with 17 funds opening new positions, 16 increasing their positions, 6 reducing their positions, and 3 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more funds holding
Funds holding: →
more ownership
Funds ownership: →
14% less capital invested
Capital invested by funds: $386M → $334M (-$52.2M)
40% less funds holding in top 10
Funds holding in top 10: 5 → 3 (-2)
Holders
47
Holding in Top 10
3
Calls
–
Puts
–
Top Buyers
| 1 | +$1.51M | |
| 2 | +$677K | |
| 3 | +$669K | |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$572K |
| 5 |
BlackRock
New York
|
+$546K |
Top Sellers
| 1 | -$1.5M | |
| 2 | -$1.36M | |
| 3 | -$920K | |
| 4 |
TCM
TCG Crossover Management
Palo Alto,
California
|
-$774K |
| 5 |
Goldman Sachs
New York
|
-$648K |